Different strains of Toxoplasma gondii induce different cytokine responses in CBA/Ca mice

Infection and Immunity

Volumn 71, Issue 7, 2003, Pages 4171-4174

  Araujo, Fausto G ^a,b   Slifer, Teri ^a  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b PAMF   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PROTEIN P40; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENCEPHALITIS; HUMAN; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STRAIN DIFFERENCE; TOXOPLASMA GONDII; TOXOPLASMIC ENCEPHALITIS;

ANIMALS; CYTOKINES; ENCEPHALITIS; HUMANS; MICE; MICE, INBRED CBA; SPECIES SPECIFICITY; TOXOPLASMA; TOXOPLASMOSIS, CEREBRAL; VIRULENCE;

EID: 0038648653     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.7.4171-4174.2003     Document Type: Article

References (19)

1. +) T lymphocytes prevents development of resistance to Toxoplasma gondii in mice. Infect. Immun. 59:1614-1619.
2. Araujo, F. G., A. A. Khan, T. L. Slifer, A. Bryskier, and J. S. Remington. 1997. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob. Agents Chemother. 41:2137-2140.
3. Araujo, F. G., and J. S. Remington. 1992. Recent advances in the search for new drugs for treatment of toxoplasmosis. Int. J. Antimicrob. Agents 1:153-164.
4. Araujo, F. G., Y. Suzuki, and J. S. Remington. 1996. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Eur. J. Clin. Microbiol. Infect. Dis. 15:394-397.
5. Gazzinelli, R. A., I. Eltoum, T. A. Wynn, and A. Sher. 1993. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J. Immunol. 151:3672-3681.
6. Grigg, M. E., S. Bonnefoy, A. B. Hehl, Y. Suzuki, and J. C. Boothroyd. 2001. Success and virulence in Toxoplasma as the result of sexual recombination between two distinct ancestries. Science 294:161-165.
7. Howe, D. K., S. Honoré, F. Derouin, and L. D. Sibley. 1997. Determination of genotypes of Toxoplasma gondii strains isolated from patients with toxoplasmosis. J. Clin. Microbiol. 35:1411-1414.
8. Howe, D. K., and L. D. Sibley. 1995. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J. Infect. Dis. 172:1561-1566.
9. Hunter, C. A., Y. Suzuki, C. S. Subauste, and J. S. Remington. 1996. Cells and cytokines in resistance to Toxoplasma gondii. Curr. Top. Microbiol. Immunol. 219:113-125.
10. + T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J. Exp. Med. 184:597-607.
11. Liesenfeld, O., J. C. Kosek, and Y. Suzuki. 1997. Gamma interferon induces Fas-dependent apoptosis of Peyer's patch T cells in mice following peroral infection with Toxoplasma gondii. Infect. Immun. 65:4682-4689.
12. Montoya, J. G., and J. S. Remington. 2000. Toxoplasmosis, p. 2858-2888. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, Pa.
13. Mordue, D. G., F. Monroy, M. La Regina, C. A. Dinarello, and L. D. Sibley. 2001. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J. Immunol. 167:4574-4584.
14. Sharma, S. D., J. M. Hofflin, and J. S. Remington. 1985. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J. Immunol. 135:4160-4163.
15. Sibley, L. D., and D. K. Howe. 1996. Genetic basis of pathogenicity in toxoplasmosis. Curr. Top. Microbiol. Immunol. 219:3-16.
16. Suzuki, Y., F. K. Conley, and J. S. Remington. 1989. Differences in virulence and development of encephalitis during chronic infection vary with the strain of Toxoplasma gondii. J. Infect. Dis. 159:790-794.
17. Suzuki, Y., F. K. Conley, and J. S. Remington. 1990. Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon. Infect. Immun. 58:3050-3055.
18. Suzuki, Y., and J. S. Remington. 2000. Immunopathogenesis of CNS toxoplasmosis, 143-162. In P. K. Peterson, and J. S. Remington (ed.), New concepts in the immunopathogenesis of CNS infections. Blackwell Science, Boston, Mass.
19. Suzuki, Y., Q. Yang, S. Yang, N. Nguyen, S. Lim, O. Liesenfeld, T. Kojima, and J. S. Remington. 1996. IL-4 is protective against development of toxoplasmic encephalitis. J. Immunol. 157:2564-2569.